Sabin Vaccine Institute Joins Coalition Dedicated to Preventing Future Epidemics

Geneva, Switzerland – November 18, 2016 – Today, the Sabin Vaccine Institute (Sabin) begins its formal membership with the Coalition for Epidemic Preparedness Innovations (CEPI), as global health leaders gather in Geneva, Switzerland for the first meeting of CEPI’s Joint Coordination Group (JCG).

Pope Francis, Sabin President Discuss Goals of the Catholic Church during Conference on Neglected Tropical Diseases

Vatican City – November 10, 2016 –Peter Hotez, M.D., Ph.D., president of the Sabin Vaccine Institute (Sabin) and director of the Sabin Product Development Partnership (Sabin PDP), today will help kick off the first-ever Vatican conference on neglected tropical diseases (NTDs) and rare diseases with a keynote address.

Sabin Vaccine Institute Partners with King Saud University to Build Vaccine Research and Development Capacity in Saudi Arabia

WASHINGTON, D.C. — June 22, 2016 — The Sabin Vaccine Institute is partnering with King Saud University (KSU) in Riyadh, Saudi Arabia, to advance vaccine research and development capacity in the Middle East and North Africa. As part of the new $6.6 million agreement, Saudi scientists will receive technical training in vaccine development at the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) laboratories in Houston, Texas.

Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.

Statement on the World Health Organization’s Declaration of a Public Health Emergency International Concern for Zika Virus

WASHINGTON, D.C. — Feb. 8, 2016 — On Monday, the World Health Organization (WHO) Director-General, Dr. Margaret Chan, declared Zika a Public Health Emergency International Concern (PHEIC), because of growing concerns of the suspected association between Zika and the rise in detected cases of congenital malformations and neurological complications in newborn babies.

Kenneth Kelley and Jordan Orange Join Sabin Vaccine Institute Board of Trustees

WASHINGTON, D.C. — January 13, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Kenneth Kelley, M.B.A., and Jordan Orange, M.D., Ph.D., to its Board of Trustees. Mr. Kelley is a Harvard Senior Advanced Leadership Fellow, focusing on global health, biosecurity and the market inefficiency leading to a lack of vaccines against neglected tropical diseases (NTDs) and emerging pandemic threats. Dr. Orange is chief of Immunology, Allergy and Rheumatology, and professor and section head for Immunology, Allergy and Rheumatology in the pediatrics department at Baylor College of Medicine.

Axel Hoos, Peter Thoren Appointed Chairman, Vice Chairman of Sabin Board of Trustees

WASHINGTON, D.C. — January 5, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the Board of Trustees unanimously appointed Axel Hoos, M.D., Ph.D., to serve as chairman of the board, and Peter L. Thoren to serve as vice chairman. Both were appointed to interim positions in December 2014.